CORRECTION: NewcelX Announces $1.55M Private Placement Of 471,125 Common Shares And One Series Of Warrants At A Price Of $3.29 Per Share

NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $3.29 per share, representing a 20% premium to the last closing price of the Company’s common shares on November 6, 2026.

Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 471,125 common shares and one series of warrants to purchase an aggregate of 353,344 common shares at an exercise price of $3.75 per share, which is 137% of the last closing price of the Company’s common shares on November 6, 2026.

The offering includes participation from existing shareholders and is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering, together with its current cash position, and previously announced $25 million equity line, primarily to advance NCEL-101, NewcelX’s lead program for type 1 diabetes, in collaboration with Eledon Pharmaceuticals, and specifically to initiate the FDA-required IND-enabling toxicology study, advance cell manufacturing capabilities and support preparations for the planned Phase 1/2a clinical trial in 2027, and for working capital and general corporate purposes.